OmniAb To Present High-Throughput Single B-cell Screening xPloration Data At The 20th Annual PEGS Boston Summit

5/15/24 4:28:26 PM ET

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Get the next $OABI alert in real time by email

Technical synergies between xPloration, OmniFlic®, OmniClic® and OmniDeep®

enable new bispecific antibody discovery workflows for OmniAb's partners

OmniAb, Inc. (NASDAQ:OABI) today announced its participation in the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the Omni Hotel. Earlier today the Company presented an overview of xPloration, a high-throughput single B-cell screening platform that leverages machine learning and Artificial Intelligence (AI), in a presentation titled "Deep Screening in Harmony with Artificial Intelligence for Bispecific Antibody Discovery."

Get the next $OABI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$OABI

Date	Price Target	Rating	Analyst
11/29/2023	$6.00	Outperform	RBC Capital Mkts
4/21/2023	$8.00	Buy	The Benchmark Company
4/13/2023	$10.00	Buy	Craig Hallum
2/22/2023	$10.00	Outperform	Cowen
2/13/2023	$11.00	Buy	H.C. Wainwright

More analyst ratings

$OABI
Financials

Live finance-specific insights

OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights
Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program updates. "We are pleased to report another successful quarter demonstrating our continued commitment to innovation with the expansion of our technology platform and a growing partnership portfolio. Third quarter results reflect consistent growth across key metrics, driven by our planned initiatives and the dedication of our team," said Matt Foehr, Chief Executive Officer of OmniAb. "Our business is well capitalized, and we have a highly scalable model with cutting-
11/12/24 4:05:00 PM ET
$OABI
Biotechnology: Commercial Physical & Biological Resarch
Health Care
OmniAb to Report Third Quarter 2024 Financial Results on November 12
OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on Tuesday, November 12, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss third quarter financial results and business updates Date: Tuesday, November 12, 2024 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Phone: U.S. (800) 549 8228 International (289) 819 1520 Conference ID is 943
10/22/24 8:00:00 AM ET
$OABI
Biotechnology: Commercial Physical & Biological Resarch
Health Care
OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights
Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and six months ended June 30, 2024, and provided operating and partner program updates. "Second quarter results were in-line with our expectations and support our view of the full year. We advanced our business by adding new partnerships and programs as existing partners made important clinical progress in their respective programs," said Matt Foehr, Chief Executive Officer of OmniAb. "With recent momentum in business development, 2024 has the potential to be a record year in terms of deal flow, which we believe is driven by the quality and differe
8/8/24 4:05:00 PM ET
$OABI
Biotechnology: Commercial Physical & Biological Resarch
Health Care

$OABI
Press Releases

Fastest customizable press release news feed in the world

OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights
Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program updates. "We are pleased to report another successful quarter demonstrating our continued commitment to innovation with the expansion of our technology platform and a growing partnership portfolio. Third quarter results reflect consistent growth across key metrics, driven by our planned initiatives and the dedication of our team," said Matt Foehr, Chief Executive Officer of OmniAb. "Our business is well capitalized, and we have a highly scalable model with cutting-
11/12/24 4:05:00 PM ET
$OABI
Biotechnology: Commercial Physical & Biological Resarch
Health Care
OmniAb to Participate in Two Investor Conferences in November
OmniAb, Inc. (NASDAQ:OABI) today announced that management will be participating in two investor conferences during the month of November. Stifel 2024 Healthcare Conference, November 18-19 at the Lotte New York Palace Hotel. Kurt Gustafson, Chief Financial Officer, will participate in one-on-one meetings with investors on Tuesday, November 19th. Jefferies London Healthcare Conference, November 19-21 at the Waldorf Hilton. Matt Foehr, Chief Executive Officer, will participate in one-on-one and small-group meetings with investors on November 19-20. About OmniAb® OmniAb licenses cutting edge discovery research technology to the pharmaceutical and biotech industry to enable the discover
10/30/24 8:00:00 AM ET
$OABI
Biotechnology: Commercial Physical & Biological Resarch
Health Care
OmniAb to Report Third Quarter 2024 Financial Results on November 12
OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on Tuesday, November 12, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss third quarter financial results and business updates Date: Tuesday, November 12, 2024 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Phone: U.S. (800) 549 8228 International (289) 819 1520 Conference ID is 943
10/22/24 8:00:00 AM ET
$OABI
Biotechnology: Commercial Physical & Biological Resarch
Health Care

OmniAb To Present High-Throughput Single B-cell Screening xPloration Data At The 20th Annual PEGS Boston Summit

Chat with this insight

Recent Analyst Ratings for $OABI

$OABI Leadership Updates

Live Leadership Updates

OmniAb Appoints Steve Love to its Board of Directors

$OABI Financials

Live finance-specific insights

OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights

OmniAb to Report Third Quarter 2024 Financial Results on November 12

OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights

$OABI Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by OmniAb Inc.

Amendment: SEC Form SC 13D/A filed by OmniAb Inc.

$OABI Press Releases

Fastest customizable press release news feed in the world

OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights

OmniAb to Participate in Two Investor Conferences in November

OmniAb to Report Third Quarter 2024 Financial Results on November 12

$OABI Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Bertozzi Carolyn R converted options into 17,769 shares, increasing direct ownership by 47% to 55,539 units (SEC Form 4)

Director Love Steven converted options into 13,333 shares (SEC Form 4)

Director Cochran Jennifer R. converted options into 1,896 shares, increasing direct ownership by 2% to 115,274 units (SEC Form 4)

$OABI Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

RBC Capital Mkts initiated coverage on OmniAb with a new price target

The Benchmark Company initiated coverage on OmniAb with a new price target

Craig Hallum initiated coverage on OmniAb with a new price target

$OABI SEC Filings

SEC Form 10-Q filed by OmniAb Inc.

OmniAb Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 10-Q filed by OmniAb Inc.

$OABI Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Foehr Matthew W bought $1,059,840 worth of shares (240,000 units at $4.42), increasing direct ownership by 7% to 3,536,665 units (SEC Form 4)

Foehr Matthew W bought $1,167,750 worth of shares (225,000 units at $5.19), increasing direct ownership by 8% to 2,908,803 units (SEC Form 4)

$OABI Market Insights

Live Market Insights

OmniAb Announced Publication Of Peer-Reviewed Paper Titled "Chickens with a Truncated Light Chain Transgene Express Single-Domain H Chain-Only Antibodies" In Journal Of Immunology